During the last ten years, the formulation of drugs as nanocrystals has rapidly evolved into a mature drug delivery strategy, with currently five products on the market. The major characteristic of these systems is the rapid dissolution velocity, enabling bioavailability enhancement after oral administration. This study describes the preparation of a solid dosage capsule form of spray-dried curcumin nanocrystal and compares its dissolution behavior with market capsule in different media. The aim was to obtain a stable nanocrystal loaded drug capsule with an increased drug saturation solubility and dissolution velocity. The solubility and dissolution experiments were performed to verify the obvious improvement of the dissolution behavior compared with commercial product. Improved dissolution behavior in drug nanocrystal-loaded solid dosage forms should lead to better bioavailability of poorly soluble drugs in the body.

References

References
1.
Shishodia
,
S.
,
Sethi
,
G.
, and
Aggarwal
,
B. B.
,
2005
, “
Curcumin: Getting Back to the Roots
,”
Ann. N.Y. Acad. Sci.
,
1056
, pp.
206
217
.10.1196/annals.1352.010
2.
Chattopadhyay
,
K.
,
Biswas
,
U.
,
Bandyopadhyay
, and
Banerjee
,
R. K.
,
2004
, “
Turmeric and Curcumin: Biological Actions and Medicinal Applications
,”
Curr. Sci.
,
87
, pp.
44
53
. Available at http://goldenmilk.net/pdfs/Curcumin_Medicinal_Appications_Chattopadhyay_etal.pdf
3.
Duke
,
J. A.
,
2002
,
CRC Handbook of Medicinal Spices
,
CRC
Press,
Boca Raton, FL
, pp.
137
144
.
4.
Ammon
,
H. P. T.
, and
Wahl
,
M. A.
,
1991
, “
Pharmacology of Curcumin
,”
Planta Med.
,
57
, pp.
1
7
.10.1055/s-2006-960004
5.
Aggarwal
,
B. B.
,
Sundaram
,
C.
,
Malani
,
N.
, and
Ichikawa
,
H.
,
2007
, “
Curcumin: The Indian Solid Gold
,” The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease (Advances in Experimental Medicine and Biology), Vol. 595,
Springer
, New York, pp.
1
75
.10.1007/978-0-387-46401-5
6.
Hatcher
,
H.
,
Planalp
,
R.
,
Cho
,
J.
,
Torti
,
F. M.
, and
Torti
,
S. V.
,
2008
, “
Curcumin: From Ancient Medicine to Current Clinical Trials
,”
Cell. Mol. Life Sci.
,
65
(
11
), pp.
1631
1652
.10.1007/s00018-008-7452-4
7.
Joe
,
B.
,
Vijaykumar
,
M.
, and
Lokesh
,
B. R.
,
2004
, “
Biological Properties of Curcumin-Cellular and Molecular Mechanisms of Action
,”
Crit. Rev. Food Sci. Nutr.
,
44
, pp.
97
111
.10.1080/10408690490424702
8.
Mancuso
,
C.
, and
Barone
,
E.
,
2009
, “
Curcumin in Clinical Practice: Myth or Reality?
,”
Trends Pharm. Sci.
,
30
(
7
), pp.
333
334
.10.1016/j.tips.2009.04.004
9.
Maheshwari
,
R. K.
,
Singh
,
A. K.
,
Gaddipati
,
J.
, and
Srimal
,
R. C.
,
2006
, “
Multiple Biological Activities of Curcumin: A Short Review
,”
Life Sci.
,
78
, pp.
2081
2087
.10.1016/j.lfs.2005.12.007
10.
Duvoix
,
A.
,
Blasius
,
R.
,
Delhalle
,
S.
,
Schnekenburger
,
M.
,
Morceau
,
F.
,
Henry
,
E.
,
Dicato
,
M.
, and
Diederich
,
M.
,
2005
, “
Chemopreventive and Therapeutic Effects of Curcumin
,”
Cancer Lett.
,
223
, pp.
181
190
.10.1016/j.canlet.2004.09.041
11.
12.
Tonnesen
,
H. H.
, and
Karlsen
,
J.
,
1985
, “
Studies of Curcumin and Curcuminoids: V. Alkaline Degradation of Curcumin
,”
Z. Lebensm. Unters. Forsch.
,
180
, pp.
132
134
.10.1007/BF01042637
13.
Anand
,
P.
,
Kunnumakkara
,
A. B.
,
Newman
,
R. A.
, and
Aggarwal
,
B. B.
,
2007
, “
Bioavailability of Curcumin: Problems and Promises
,”
Mol. Pharm.
,
4
(
6
), pp.
807
818
.10.1021/mp700113r
14.
Bansal
,
A. K.
,
Munjal
,
B.
, and
Patel
,
S.
,
2009
, “
Novel Self-Emulsifying Curcumin Compositions With Enhanced Bioavailability
,” PCT Filed 2 April 2009, No. PCT/IB/2009/005154.
15.
Bansal
,
A. K.
,
Munjal
,
B.
, and
Patel
,
S.
,
2008
, “
Novel Self Nano Emulsifying Curcumin (Curcuminoids) Composition With Enhanced Bioavailability
,” Indian Patent Application Filed 24 July 2008, No. 1776/DEL/2008.
16.
Lao
,
C. D.
,
Ruffin
,
M. T.
,
Normolle
,
D.
,
Heath
,
D. D.
,
Murray
,
S.
I
.,
Bailey
,
J. M.
,
Boggs
,
M. E.
,
Crowell
,
J.
,
Rock
,
C. L.
, and
Brenner
,
D. E.
,
2006
, “
Dose Escalation of a Curcuminoid Formulation
,”
BMC Compl. Altern. Med.
,
6
,
p
. 10.10.1186/1472-6882-6-10
17.
Shoba
,
G.
,
Joy
,
D.
,
Joseph
,
T.
,
Majeed
,
M.
,
Rajendran
,
R.
, and
Srinivas
,
P. S.
,
1998
, “
Influence of Piperine on the Pharmacokinetics of Curcumin in Animals and Human Volunteers
,”
Planta Med.
,
64
, pp.
353
356
.10.1055/s-2006-957450
18.
Li
,
L.
,
Braiteh
,
F. S.
, and
Kurzrock
,
R.
,
2005
, “
Liposome-Encapsulated Curcumin: In Vitro and In Vivo Effects on Proliferation, Apoptosis, Signaling, and Angiogenesis
,”
Cancer
,
104
, pp.
1322
1331
.10.1002/cncr.21300
19.
Bisht
,
S.
,
Feldmann
,
G.
,
Soni
,
S.
,
Ravi
,
R.
,
Karikar
,
C.
,
Maitra
,
A.
, and
Maitra
,
A.
,
2007
, “
Polymeric Nanoparticle-Encapsulated Curcumin (‘Nanocurcumin’): A Novel Strategy for Human Cancer Therapy
,”
J. Nanobiotechn. (BioMed Central)
,
5
(
3
), p.
3
.10.1186/1477-3155-5-3
20.
Liu
,
A.
,
Lou
,
H.
,
Zhao
,
L.
, and
Fan
,
P.
,
2006
, “
Validated LC/MS/MS Assay for Curcumin and Tetrahydrocurcumin in Rat Plasma and Application to Pharmacokinetic Study of Phospholipids Complex of Curcumin
,”
J. Pharm. Biomed. Anal.
,
40
, pp.
720
727
.10.1016/j.jpba.2005.09.032
21.
Thomas
,
S. L.
,
Zhong
,
D.
,
Zhou
,
W.
,
Malik
,
S. W.
,
Liotta
,
D.
,
Snyder
,
J. P.
,
Hamel
,
E.
, and
Giannakakou
,
P.
,
2008
, “
EF24, a Novel Curcumin Analog, Disrupts the Microtubule Cytoskeleton and Inhibits HIF-1,” Cell Cycle
,
7
(
15
), pp.
2409
2417
.
22.
Hatcher
,
H.
,
Planalp
,
R.
,
Cho
,
J.
,
Torti
,
F. M.
, and
Torti
,
S. V.
,
2008
, “
Curcumin: From Ancient Medicine to Current Clinical Trials
,”
J. Cell. Mol. Life Sci.
,
65
(
11
), pp.
1631
1652
.10.1007/s00018-008-7452-4
23.
Ravichandran
,
R.
,
2009
, “
Nanoparticles in Drug Delivery: Potential Green Nanobiomedicine Applications
,”
Int. J. Green Nanotech. Biomed.
,
1
(
2
), pp.
B108
B130
10.1080/19430850903430427.
24.
Ravichandran
,
R.
,
2010
, “
Nanotechnology-Based Drug Delivery Systems
,”
NanoBiotechnology
,
5
(
1
), pp.
17
33
10.1007/s12030-009-9028-2
25.
Chen
,
X.
,
Young
,
T. J.
,
Sarkari
,
M.
,
Williams
,
R. O.
, and
Johnston
,
K. P.
,
2002
, “
Preparation of Cyclosporine a Nanoparticles by Evaporative Precipitation Into Aqueous Solution
,”
Int. J. Pharm.
,
242
, pp.
3
14
.10.1016/S0378-5173(02)00147-3
26.
Muller
,
R. H.
,
Jacobs
,
C.
, and
Kayser
,
O.
,
2001
, “
Nanosuspensions as Particulate Drug Formulations in Therapy: Rationale for Development and What We Can Expect for the Future
,”
Adv. Drug Del. Rev.
,
47
, pp.
3
19
.10.1016/S0169-409X(00)00118-6
27.
Weder
,
H. G.
, and
van Hoogevest
,
P.
,
1998
, “
Nanosuspensions for Intravenous Administration
,” U.S. Patent No. 5726164.
28.
Muller
,
R. H.
, and
Jacobs
,
C.
,
2002
, “
Buparvaquone Mucoadhesive Nanosuspensions: Preparation, Optimisation and Long-Term Stability
,”
Int. J. Pharm.
,
237
, pp.
151
161
.10.1016/S0378-5173(02)00040-6
29.
Rabinow
,
B. E.
,
2004
, “
Nanosuspensions in Drug Delivery
,”
Nat. Rev. Drug Discov.
,
3
, pp.
785
796
.10.1038/nrd1494
30.
Keck
,
C. M.
, and
Muller
,
R. H.
,
2006
, “
Drug Nanocrystals of Poorly Soluble Drugs Produced by High Pressure Homogenization
,”
Eur. J. Pharm. Biopharm.
,
62
(
1
), pp.
3
16
.10.1016/j.ejpb.2005.05.009
31.
Liversidge
,
G. G.
, and
Cundy
,
K. C.
,
1995
, “
Particle Size Reduction for Improvement of Oral Bioavailability of Hydrophobic Drugs: I. Absolute Oral Bioavailability of Nanocrystalline Danazol in Beagle Dogs
,”
Int. J. Pharm.
,
125
, pp.
91
97
.10.1016/0378-5173(95)00122-Y
32.
Jinno
,
J.
,
Naoki
,
K.
,
Miyake
,
M.
,
Yamada
,
K.
,
Mukia
,
T.
,
Odomi
,
M.
,
Togu-chi
,
H.
,
Liversidge
,
G. G.
,
Higaki
,
K.
, and
Kimura
,
T.
,
2006
, “
Effect of Particle Size Reduction on Dissolution and Oral Absorption of a Poorly Water-Soluble Drug, Cilostazol, in Beagle Dogs
,”
J. Control. Release
,
111
, pp.
56
64
.10.1016/j.jconrel.2005.11.013
33.
Liversidge
,
G. G.
, and
Conzentino
,
P.
,
1995
, “
Drug Particle Size Reduction for Decreasing Gastric Irritancy and Enhancing Absorption of Naproxen in Rats
,”
Int. J. Pharm.
,
125
, pp.
309
313
.10.1016/0378-5173(95)00148-C
34.
Gao
,
L.
,
Zhang
,
D.
, and
Chen
,
M.
,
2008
, “
Drug Nanocrystals for the Formulation of Poorly Soluble Drugs and Its Application as a Potential Drug Delivery System
,”
J. Nanoparticle Res.
,
10
(
5
), pp.
845
862
.10.1007/s11051-008-9357-4
35.
Ravichandran
,
R.
,
2010
, “
Preparation and Characterisation of Curcumin Nanosuspension for Enhanced Solubility and Dissolution Velocity
,”
Int. J. Nano Biomater.
,
3
(
2
), pp.
153
186
.10.1504/IJNBM.2010.037803
36.
Donsì
,
F.
,
Wang
,
Y.
,
Li
,
J.
, and
Huang
,
Q.
,
2010
, “
Preparation of Curcumin Sub-Micrometer Dispersions by High-Pressure Homogenization
,”
J. Agric. Food Chem.
,
58
(
5
),
pp. 2848
2853
.10.1021/jf903968x
37.
Noyes
,
A. A.
, and
Whitney
,
W. R.
,
1897
, “
The Rate of Solution of Solid Substances in Their Own Solutions
,”
J. Am. Chem. Soc.
,
19
, pp.
930
934
.10.1021/ja02086a003
38.
Muller
,
R. H.
,
Jacobs
,
C.
, and
Kayser
,
O.
,
2000
, “
Nanosuspensions for the Formulation of Poorly Soluble Drugs
,”
Pharmaceutical Emulsions and Suspensions
,
F.
Nielloudand
, and
G.
Marti-Mestres
, eds.,
Marcel Dekker
,
New York
, pp.
383
407
.
39.
Muller
,
R. H.
, and
Akkar
,
A.
,
2004
, “
Drug Nanocrystals of Poorly Soluble Drugs
,”
Encyclopedia of Nanoscience and Nanotechnology
,
H. S.
Nalwa
, ed.,
American Scientific
,
Los Angeles, CA
, pp.
627
638
.
40.
Takano
,
R.
,
Furumoto
,
K.
,
Shiraki
,
K.
,
Takata
,
N.
,
Hayashi
,
Y.
,
Aso
,
Y.
, and
Yamashita
,
S.
,
2008
, “
Rate-Limiting Steps of Oral Absorption for Poorly Water-Soluble Drugs in Dogs; Prediction From a Miniscale Dissolution Test and a Physiologically-Based Computer Simulation
,”
Pharm. Res.
,
25
(
10
), pp.
2334
2344
.10.1007/s11095-008-9637-9
41.
Hintz
,
R. J.
, and
Johnson
,
K. C.
,
1989
, “
The Effect of Particle Size Distribution on Dissolution Rate and Oral Absorption
,”
Int. J. Pharm.
,
51
, pp.
9
17
.10.1016/0378-5173(89)90069-0
42.
Keck
,
C.
,
Fichtinger
,
A.
,
Viernstein
,
H.
, and
Muller
,
R. H.
,
2004
, “
Oral Drug Nanocrystals—Effect of Potential Aggregation on Bioavailability
,”
Annual Meeting of Pharmaceutical Scientists (AAPS)
, Baltimore, MD, p.
2746
.
You do not currently have access to this content.